Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 14, 2017. The document serves as a transaction notification reporting share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions were executed on the London Stock Exchange (XLON) on July 13, 2017.
Key Financial Metrics
The filing does not report company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Instrument | Transaction Type | Price per Share | Total Volume |
|---|---|---|---|
| Ordinary Shares (25 pence each) | Acquisition via Dividend Re-investment | £16.2549 | 322 shares |
Note: The total volume of 322 shares is the aggregate of individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine administrative transactions where dividends paid on July 13, 2017, were automatically re-invested to purchase additional shares under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ordinary shares resulting from the re-investment of dividends, not open-market purchases or sales.
- Participants: The transactions involved 10 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Valuation: The share price at the time of transaction was £16.2549.
- Scope: This filing does not provide financial performance data; investors should refer to GSK's Form 20-F or interim reports for revenue and earnings information.